Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial-Reference-Cited by-同舟云学术

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Published:2014-08 Issue:9944 Volume:384 Page:665-673
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Garon Edward B,Ciuleanu Tudor-Eliade,Arrieta Oscar,Prabhash Kumar,Syrigos Konstantinos N,Goksel Tuncay,Park Keunchil,Gorbunova Vera,Kowalyszyn Ruben Dario,Pikiel Joanna,Czyzewicz Grzegorz,Orlov Sergey V,Lewanski Conrad R,Thomas Michael,Bidoli Paolo,Dakhil Shaker,Gans Steven,Kim Joo-Hang,Grigorescu Alexandru,Karaseva Nina,Reck Martin,Cappuzzo Federico,Alexandris Ekaterine,Sashegyi Andreas,Yurasov Sergey,Pérol Maurice

Publisher

Elsevier BV

Subject

General Medicine

Reference33 articles.

1. Cancer statistics 2012;Siegel;CA Cancer J Clin,2012

2. Genotyping and genomic profiling of non-small cell-lung cancer: implications for current and future therapies;Li;J Clin Oncol,2013

3. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line;Leighl;Curr Oncol,2012

4. Maintenance chemotherapy for advanced non-small cell lung cancer: new life for an old idea;Gerber;J Clin Oncol,2013

5. Current treatments for advanced stage non-small cell lung cancer;Stinchcombe;Proc Am Thorac Soc,2009

Cited by 1086 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer;International Journal of Molecular Sciences;2024-09-12

2. Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine;Life;2024-09-10

3. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study;Journal of Clinical Oncology;2024-09-09

4. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial;The Lancet Respiratory Medicine;2024-09

5. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR-Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial;Journal of Clinical Oncology;2024-09-01